Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

Abstract: A system for filtering a gas-solids mixture, comprises: a housing; a separating body dividing the housing in a raw gas chamber and a clean gas chamber, the raw gas chamber being accessible via an inlet for the gas-solids mixture and the clean gas chamber comprising an outlet for discharging a cleaned gas; a number of filter elements suspended from the separating body; lower ends of the filter elements being connected to a support grid, the support grid comprising a number of arms; one or more cleaning elements provided on the arms of the support grid for cleaning thereof.

Abstract: A method and a system for reoptimizing unmanned aerial vehicle formation communication topology based on minimum cost arborescence are used for optimizing reconstructed UAV formation communication topology after a communication failure occurs on the UAVs in the formation. The method includes calculating a first communication cost of the reconstructed UAV formation communication topology; comparing the first communication cost with a target communication cost for the minimum cost arborescence of the formation communication diagram under a predetermined state; when the first communication cost is greater than the target communication cost for the minimum cost arborescence of the formation communication diagram under the predetermined state, optimizing the reconstructed UAV formation communication topology through a predetermined strategy.

Abstract: The present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.

Abstract: A networking system comprising a virtual group controller in an information centric network configured to enable mobility and security for a plurality of users groups of the information centric network, a plurality of user groups coupled to the virtual group controller and associated with the users, a plurality of agents that are each associated with one of the user groups, and a database for trusted service profile coupled to the virtual group controller, wherein the virtual group controller is configured to interact with the agents to enable mobility for the user groups using a server-less domain-based naming scheme.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

Abstract: The present invention relates to an optical module and optical module system using the same. The optical module comprises a transceiving unit, an antenna and an MCU. The transceiving unit receives control commands from one or more control computers via the antenna and transfers them to the MCU. Then the MCU processes the control commands and provides feedback information to the one or more control computers through the transceiving unit. In the optical module of the present invention, as a result of an additional IOT wireless unit, the optical module is capable of communicating with remote control computers, thereby achieving remote testing and control for optical modules, instead of using conventional control methods for optical modules.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: A data device controls distribution of data to user devices through an edge router via an encryption scheme. The data device encrypts data using a first key and a public key, and sends the data to the edge router. The edge router encrypts the encrypted data with a second key and sends the re-encrypted data to a user device. The data device then authenticates the user device and issues a decryption key derived from a private key corresponding to the public key, the first key, and the second key to the user device. The user device uses the decryption key to decrypt and access the data.

Abstract: An anchor server in an information-centric network (ICN) receives registration and deregistration requests from one or more producers in the ICN. In response to a producer initially registering, the anchor server stores records associating the producer with content available from the producer via a first point of attachment. In response to the producer deregistering, the records are marked as deactivated. While the records are deactivated, requests for the content from consumers may be queued. In response to the producer reregistering as being connected to the ICN via a second point of attachment, the queued requests are forwarded to the producer via the second point of attachment.

Abstract: A network element (NE) comprising a memory configured to store a digest log for a conference, a receiver coupled to the memory and configured to receive a first message from a first of a plurality of service proxies of the conference, wherein the first message comprises a signature profile of a first of a plurality of participants of the conference associated with the first service proxy, a processor coupled to the receiver and the memory and configured to track a state of the conference by updating the digest log according to the first message, and a transmitter coupled to the processor and configured to send a plurality of second messages to indicate the digest log update to the service proxies without a transmission request from the service proxies.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: A system for filtering a gas-solids mixture, comprises: a housing a separating body dividing the housing in a raw gas chamber and a clean gas chamber, the raw gas chamber being accessible via an inlet for the gas-solids mixture and the clean gas chamber comprising an outlet for discharging a cleaned gas; a number of filter elements suspended from the separating body; lower ends of the filter elements being connected to a support grid the support grid comprising a number of arms; one or more cleaning elements provided on the arms of the support grid for cleaning thereof.